The Promise of IL-21 Engineered NK Cells in Glioblastoma Treatment - Targeted Oncology
IL-21 NK cells show promise in treating glioblastoma, outperforming IL-15 NK cells in safety and tumor control. Direct brain injection of IL-15 NK cells was toxic, contrasting with the safety of IL-21 NK cells. Research aims to initiate a clinical trial for IL-21 armored NK cells targeting glioblastoma antigens by 2025.
Reference News
The Promise of IL-21 Engineered NK Cells in Glioblastoma Treatment - Targeted Oncology
IL-21 NK cells show promise in treating glioblastoma, outperforming IL-15 NK cells in safety and tumor control. Direct brain injection of IL-15 NK cells was toxic, contrasting with the safety of IL-21 NK cells. Research aims to initiate a clinical trial for IL-21 armored NK cells targeting glioblastoma antigens by 2025.